Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Tislelizumab in recurrent/metastatic nasopharyngeal carcinoma
NCT05981157Phase 2Recruiting
- Sponsor
- Zhongshan People's Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib and tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Zhongshan People's Hospital. Primary endpoint: Objective Response Rate at 1 year. Started Jun 2023; status: recruiting.
02
Drugs
anlotinibtislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05981157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981157.